Abstract
The regeneration of nerve tissue after spinal cord injury is a complex and poorly understood process. Medication and surgery are not very effective treatments for patients with spinal cord injuries. Gene therapy is a popular approach for the treatment of such patients. The delivery of therapeutic genes is carried out in a variety of ways, such as direct injection of therapeutic vectors at the site of injury, retrograde delivery of vectors, and ex vivo therapy using various cells. Recombinant adenoviruses are often used as vectors for gene transfer. This review discusses the advantages, limitations and prospects of adenovectors in spinal cord injury therapy.
Highlights
Spinal cord injury (SCI) is serious medical condition, often leading to disability and a significant decrease in patients’ quality of life
Vectors based on adenovirus serotype 5 (AdV5) have found a broad range of applications in the field of gene therapy, including the transfer of various therapeutic transgenes for the treatment of SCI. rAdVs have several advantages over other viruses used for gene transfer
The rat mesenchymal stem cells (MSCs) were transduced with rAdV5 at an multiplicity of infection (MOI) of 100 with an efficiency of 20%, which increased to 60% at an MOI of 1,000 without affecting the morphology of cells or their ability to differentiate (Rooney et al, 2008)
Summary
Spinal cord injury (SCI) is serious medical condition, often leading to disability and a significant decrease in patients’ quality of life. The use of neurotrophic factors is an actively developing direction for the treatment of SCI, since they are able to suppress neuronal apoptosis and support atrophic, hypofunctional neurons. These factors quickly degrade after direct administration. Adenotherapy for Spinal Cord Injury between them is that AAVs and lentiviruses cause constant expression of a transgene, while rAdVs provide only temporary expression (Tosolini and Morris, 2016). The transplantation of an autologous peripheral nerve graft transduced with AAV producing brainderived neurotrophic factor (BDNF) or ciliary neurotrophic factor (CNTF) led to significant changes in dendritic architecture in both transduced and non-transduced populations of regenerating retinal ganglion cells after 5–8 months (Rodger et al, 2012).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
